/stocks — the workspaceLOADING
GILEAD SCIENCES, INC. (GILD) is a biological products, (no diagnostic substances) company. Piotroski F-Score 7/8. 23 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-06 from GILD's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31.
A plain-English read on GILD plus an auto-SWOT — built from GILD's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate GILD using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from GILD's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment GILD files its announcement.
GILD has rallied after 5 of its last 8 earnings reports.
Earnings reactions have been moderate.
GILD has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+8.5% and -3.6%).
A more typical earnings reaction has been approximately ±3.3%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-07 | -3.6% |
| 2026-02-10 | +2.7% |
| 2025-10-30 | +1.1% |
| 2025-08-07 | +8.3% |
| 2025-04-24 | -3.0% |
| 2025-02-11 | +8.2% |
| 2024-11-06 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +8.5% |
| 2024-08-08 | -0.5% |
| Jared MoskowitzU.S. Representative · FL-23 | BUY | $1,001 - $15,000 | filed 2026-06-19 |
| Jared MoskowitzU.S. Representative · FL-23 | BUY | $1,001 - $15,000 | filed 2026-06-19 |
| Company | Stake value | % of company owned |
|---|---|---|
| Arcellx Inc | $771.7M | — |
| Arcus Biosciences IncRCUS | $678.8M | 25.0% |
| Galapagos NV | $501.2M | — |
| Assembly Biosciences IncASMB | $125.0M | 28.3% |
| Kyverna Therapeutics IncKYTX | $35.6M | 6.8% |
| Xilio Therapeutics IncXLO | $5.5M | 11.2% |
Long US equity positions from GILD's own 13F-HR (SEC), reported quarterly and lagged up to 45 days. “% of company owned” = reported shares ÷ that company's latest shares outstanding.
| O'Day Daniel PatrickChairman & CEO | SELL | $1.9M | view → |
| Dickinson Andrew DChief Financial Officer | SELL | $376K | view → |
| Mercier JohannaChief Comm & Corp Aff Officer | SELL | $372K | view → |
| O'Day Daniel PatrickChairman & CEO | SELL | $2.0M | view → |
| Mercier JohannaChief Comm & Corp Aff Officer | SELL | $3.7M | view → |
| Dickinson Andrew DChief Financial Officer | SELL | $397K | view → |
| O'Day Daniel PatrickChairman & CEO | SELL | $1.3M | view → |
| Mercier JohannaChief Comm & Corp Aff Officer | SELL | $423K | view → |